Arvinas Secures First PROTAC Approval with VEPPANU, Licenses to Rigel
Event summary
- Arvinas received FDA approval for VEPPANU, the first PROTAC degrader, and licensed it to Rigel Pharmaceuticals.
- Company anticipates sharing clinical data from three Phase 1 programs (ARV-393, ARV-102, ARV-027) over the next 12 months.
- Presented preclinical data for HPK1 degrader program (ARV-6723) showing potential to overcome immune checkpoint inhibitor resistance in solid tumors.
- Cash position of $567.9 million as of June 30, 2026, sufficient to fund operations into the second half of 2028.
The big picture
Arvinas' FDA approval of VEPPANU marks a significant milestone for the PROTAC degrader platform, positioning it as a pioneer in targeted protein degradation therapies. The licensing deal with Rigel Pharmaceuticals underscores the commercial potential of this technology. As Arvinas advances its clinical pipeline, its ability to translate preclinical promise into clinical success will be closely watched by investors and industry peers.
What we're watching
- Clinical Pipeline Progress
- The pace at which Arvinas can deliver positive clinical data for ARV-393, ARV-102, and ARV-027 will determine investor confidence in its pipeline.
- Commercialization Strategy
- Whether Rigel Pharmaceuticals can successfully commercialize VEPPANU and expand its market reach will be critical for Arvinas' long-term revenue.
- Financial Sustainability
- How Arvinas manages its cash burn rate and secures additional funding, if needed, to support its ambitious clinical development plans.
Related topics